 | • レポートコード：QYR2104Z3544 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、悪性黒色腫治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（免疫療法、標的療法、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・悪性黒色腫治療薬の市場動向 ・企業の競争状況、市場シェア ・悪性黒色腫治療薬の種類別市場規模（免疫療法、標的療法、その他） ・悪性黒色腫治療薬の用途別市場規模（病院、クリニック、その他） ・悪性黒色腫治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・悪性黒色腫治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・悪性黒色腫治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・悪性黒色腫治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・悪性黒色腫治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bristol-Myers Squibb、Enzon Pharmaceuticals、Exelixis、GlaxoSmithKline、Merck、Pfizer、Janssen Biotech、Hoffmann-La Roche Ltd、Navidea Biopharmaceuticals、Novartis、Ono Pharmaceutical、Amgen） ・結論 |
Market Analysis and Insights: Global Malignant Melanoma Drugs Market
The global Malignant Melanoma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Malignant Melanoma Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Malignant Melanoma Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Malignant Melanoma Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Malignant Melanoma Drugs market.
Global Malignant Melanoma Drugs Scope and Market Size
Malignant Melanoma Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Melanoma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Immunotherapy
Targeted Therapy
Other
Segment by Application
Hospitals
Clinics
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Bristol-Myers Squibb
Enzon Pharmaceuticals
Exelixis
GlaxoSmithKline
Merck
Pfizer
Janssen Biotech
Hoffmann-La Roche Ltd
Navidea Biopharmaceuticals
GlaxoSmithKline
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Melanoma Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Immunotherapy
1.2.3 Targeted Therapy
1.2.4 Other
1.3 Market by Application
1.3.1 Global Malignant Melanoma Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Malignant Melanoma Drugs Market Perspective (2016-2027)
2.2 Malignant Melanoma Drugs Growth Trends by Regions
2.2.1 Malignant Melanoma Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Malignant Melanoma Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Malignant Melanoma Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Malignant Melanoma Drugs Industry Dynamic
2.3.1 Malignant Melanoma Drugs Market Trends
2.3.2 Malignant Melanoma Drugs Market Drivers
2.3.3 Malignant Melanoma Drugs Market Challenges
2.3.4 Malignant Melanoma Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Malignant Melanoma Drugs Players by Revenue
3.1.1 Global Top Malignant Melanoma Drugs Players by Revenue (2016-2021)
3.1.2 Global Malignant Melanoma Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Malignant Melanoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Malignant Melanoma Drugs Revenue
3.4 Global Malignant Melanoma Drugs Market Concentration Ratio
3.4.1 Global Malignant Melanoma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Melanoma Drugs Revenue in 2020
3.5 Malignant Melanoma Drugs Key Players Head office and Area Served
3.6 Key Players Malignant Melanoma Drugs Product Solution and Service
3.7 Date of Enter into Malignant Melanoma Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Malignant Melanoma Drugs Breakdown Data by Type
4.1 Global Malignant Melanoma Drugs Historic Market Size by Type (2016-2021)
4.2 Global Malignant Melanoma Drugs Forecasted Market Size by Type (2022-2027)
5 Malignant Melanoma Drugs Breakdown Data by Application
5.1 Global Malignant Melanoma Drugs Historic Market Size by Application (2016-2021)
5.2 Global Malignant Melanoma Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Malignant Melanoma Drugs Market Size (2016-2027)
6.2 North America Malignant Melanoma Drugs Market Size by Type
6.2.1 North America Malignant Melanoma Drugs Market Size by Type (2016-2021)
6.2.2 North America Malignant Melanoma Drugs Market Size by Type (2022-2027)
6.2.3 North America Malignant Melanoma Drugs Market Size by Type (2016-2027)
6.3 North America Malignant Melanoma Drugs Market Size by Application
6.3.1 North America Malignant Melanoma Drugs Market Size by Application (2016-2021)
6.3.2 North America Malignant Melanoma Drugs Market Size by Application (2022-2027)
6.3.3 North America Malignant Melanoma Drugs Market Size by Application (2016-2027)
6.4 North America Malignant Melanoma Drugs Market Size by Country
6.4.1 North America Malignant Melanoma Drugs Market Size by Country (2016-2021)
6.4.2 North America Malignant Melanoma Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Malignant Melanoma Drugs Market Size (2016-2027)
7.2 Europe Malignant Melanoma Drugs Market Size by Type
7.2.1 Europe Malignant Melanoma Drugs Market Size by Type (2016-2021)
7.2.2 Europe Malignant Melanoma Drugs Market Size by Type (2022-2027)
7.2.3 Europe Malignant Melanoma Drugs Market Size by Type (2016-2027)
7.3 Europe Malignant Melanoma Drugs Market Size by Application
7.3.1 Europe Malignant Melanoma Drugs Market Size by Application (2016-2021)
7.3.2 Europe Malignant Melanoma Drugs Market Size by Application (2022-2027)
7.3.3 Europe Malignant Melanoma Drugs Market Size by Application (2016-2027)
7.4 Europe Malignant Melanoma Drugs Market Size by Country
7.4.1 Europe Malignant Melanoma Drugs Market Size by Country (2016-2021)
7.4.2 Europe Malignant Melanoma Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Malignant Melanoma Drugs Market Size (2016-2027)
8.2 Asia-Pacific Malignant Melanoma Drugs Market Size by Type
8.2.1 Asia-Pacific Malignant Melanoma Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Malignant Melanoma Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Malignant Melanoma Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Malignant Melanoma Drugs Market Size by Application
8.3.1 Asia-Pacific Malignant Melanoma Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Malignant Melanoma Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Malignant Melanoma Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Malignant Melanoma Drugs Market Size by Region
8.4.1 Asia-Pacific Malignant Melanoma Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Malignant Melanoma Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Malignant Melanoma Drugs Market Size (2016-2027)
9.2 Latin America Malignant Melanoma Drugs Market Size by Type
9.2.1 Latin America Malignant Melanoma Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Malignant Melanoma Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Malignant Melanoma Drugs Market Size by Type (2016-2027)
9.3 Latin America Malignant Melanoma Drugs Market Size by Application
9.3.1 Latin America Malignant Melanoma Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Malignant Melanoma Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Malignant Melanoma Drugs Market Size by Application (2016-2027)
9.4 Latin America Malignant Melanoma Drugs Market Size by Country
9.4.1 Latin America Malignant Melanoma Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Malignant Melanoma Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Malignant Melanoma Drugs Market Size (2016-2027)
10.2 Middle East & Africa Malignant Melanoma Drugs Market Size by Type
10.2.1 Middle East & Africa Malignant Melanoma Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Malignant Melanoma Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Malignant Melanoma Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Malignant Melanoma Drugs Market Size by Application
10.3.1 Middle East & Africa Malignant Melanoma Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Malignant Melanoma Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Malignant Melanoma Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Malignant Melanoma Drugs Market Size by Country
10.4.1 Middle East & Africa Malignant Melanoma Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Malignant Melanoma Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Malignant Melanoma Drugs Introduction
11.1.4 Bristol-Myers Squibb Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Enzon Pharmaceuticals
11.2.1 Enzon Pharmaceuticals Company Details
11.2.2 Enzon Pharmaceuticals Business Overview
11.2.3 Enzon Pharmaceuticals Malignant Melanoma Drugs Introduction
11.2.4 Enzon Pharmaceuticals Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.2.5 Enzon Pharmaceuticals Recent Development
11.3 Exelixis
11.3.1 Exelixis Company Details
11.3.2 Exelixis Business Overview
11.3.3 Exelixis Malignant Melanoma Drugs Introduction
11.3.4 Exelixis Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.3.5 Exelixis Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Malignant Melanoma Drugs Introduction
11.4.4 GlaxoSmithKline Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.4.5 GlaxoSmithKline Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Malignant Melanoma Drugs Introduction
11.5.4 Merck Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.5.5 Merck Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Malignant Melanoma Drugs Introduction
11.6.4 Pfizer Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.6.5 Pfizer Recent Development
11.7 Janssen Biotech
11.7.1 Janssen Biotech Company Details
11.7.2 Janssen Biotech Business Overview
11.7.3 Janssen Biotech Malignant Melanoma Drugs Introduction
11.7.4 Janssen Biotech Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.7.5 Janssen Biotech Recent Development
11.8 Hoffmann-La Roche Ltd
11.8.1 Hoffmann-La Roche Ltd Company Details
11.8.2 Hoffmann-La Roche Ltd Business Overview
11.8.3 Hoffmann-La Roche Ltd Malignant Melanoma Drugs Introduction
11.8.4 Hoffmann-La Roche Ltd Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.8.5 Hoffmann-La Roche Ltd Recent Development
11.9 Navidea Biopharmaceuticals
11.9.1 Navidea Biopharmaceuticals Company Details
11.9.2 Navidea Biopharmaceuticals Business Overview
11.9.3 Navidea Biopharmaceuticals Malignant Melanoma Drugs Introduction
11.9.4 Navidea Biopharmaceuticals Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.9.5 Navidea Biopharmaceuticals Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Malignant Melanoma Drugs Introduction
11.10.4 Novartis Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.10.5 Novartis Recent Development
11.11 Ono Pharmaceutical
11.11.1 Ono Pharmaceutical Company Details
11.11.2 Ono Pharmaceutical Business Overview
11.11.3 Ono Pharmaceutical Malignant Melanoma Drugs Introduction
11.11.4 Ono Pharmaceutical Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.11.5 Ono Pharmaceutical Recent Development
11.12 Amgen
11.12.1 Amgen Company Details
11.12.2 Amgen Business Overview
11.12.3 Amgen Malignant Melanoma Drugs Introduction
11.12.4 Amgen Revenue in Malignant Melanoma Drugs Business (2016-2021)
11.12.5 Amgen Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Malignant Melanoma Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Immunotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Other
Table 5. Global Malignant Melanoma Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Malignant Melanoma Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Malignant Melanoma Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Malignant Melanoma Drugs Market Share by Regions (2016-2021)
Table 9. Global Malignant Melanoma Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Malignant Melanoma Drugs Market Share by Regions (2022-2027)
Table 11. Malignant Melanoma Drugs Market Trends
Table 12. Malignant Melanoma Drugs Market Drivers
Table 13. Malignant Melanoma Drugs Market Challenges
Table 14. Malignant Melanoma Drugs Market Restraints
Table 15. Global Malignant Melanoma Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Malignant Melanoma Drugs Market Share by Players (2016-2021)
Table 17. Global Top Malignant Melanoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Melanoma Drugs as of 2020)
Table 18. Ranking of Global Top Malignant Melanoma Drugs Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Malignant Melanoma Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Malignant Melanoma Drugs Product Solution and Service
Table 22. Date of Enter into Malignant Melanoma Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Malignant Melanoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Malignant Melanoma Drugs Revenue Market Share by Type (2016-2021)
Table 26. Global Malignant Melanoma Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Malignant Melanoma Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Malignant Melanoma Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Malignant Melanoma Drugs Revenue Market Share by Application (2016-2021)
Table 30. Global Malignant Melanoma Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Malignant Melanoma Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Malignant Melanoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Malignant Melanoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Malignant Melanoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Malignant Melanoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Malignant Melanoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Malignant Melanoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Malignant Melanoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Malignant Melanoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Malignant Melanoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Malignant Melanoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Malignant Melanoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Malignant Melanoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Malignant Melanoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Malignant Melanoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Malignant Melanoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Malignant Melanoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Malignant Melanoma Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Malignant Melanoma Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Malignant Melanoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Malignant Melanoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Malignant Melanoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Malignant Melanoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Malignant Melanoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Malignant Melanoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Malignant Melanoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Malignant Melanoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Malignant Melanoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Malignant Melanoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Malignant Melanoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Malignant Melanoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. Bristol-Myers Squibb Company Details
Table 63. Bristol-Myers Squibb Business Overview
Table 64. Bristol-Myers Squibb Malignant Melanoma Drugs Product
Table 65. Bristol-Myers Squibb Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 66. Bristol-Myers Squibb Recent Development
Table 67. Enzon Pharmaceuticals Company Details
Table 68. Enzon Pharmaceuticals Business Overview
Table 69. Enzon Pharmaceuticals Malignant Melanoma Drugs Product
Table 70. Enzon Pharmaceuticals Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 71. Enzon Pharmaceuticals Recent Development
Table 72. Exelixis Company Details
Table 73. Exelixis Business Overview
Table 74. Exelixis Malignant Melanoma Drugs Product
Table 75. Exelixis Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 76. Exelixis Recent Development
Table 77. GlaxoSmithKline Company Details
Table 78. GlaxoSmithKline Business Overview
Table 79. GlaxoSmithKline Malignant Melanoma Drugs Product
Table 80. GlaxoSmithKline Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 81. GlaxoSmithKline Recent Development
Table 82. Merck Company Details
Table 83. Merck Business Overview
Table 84. Merck Malignant Melanoma Drugs Product
Table 85. Merck Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 86. Merck Recent Development
Table 87. Pfizer Company Details
Table 88. Pfizer Business Overview
Table 89. Pfizer Malignant Melanoma Drugs Product
Table 90. Pfizer Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 91. Pfizer Recent Development
Table 92. Janssen Biotech Company Details
Table 93. Janssen Biotech Business Overview
Table 94. Janssen Biotech Malignant Melanoma Drugs Product
Table 95. Janssen Biotech Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 96. Janssen Biotech Recent Development
Table 97. Hoffmann-La Roche Ltd Company Details
Table 98. Hoffmann-La Roche Ltd Business Overview
Table 99. Hoffmann-La Roche Ltd Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 100. Hoffmann-La Roche Ltd Recent Development
Table 101. Navidea Biopharmaceuticals Company Details
Table 102. Navidea Biopharmaceuticals Business Overview
Table 103. Navidea Biopharmaceuticals Malignant Melanoma Drugs Product
Table 104. Navidea Biopharmaceuticals Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 105. Navidea Biopharmaceuticals Recent Development
Table 106. Novartis Company Details
Table 107. Novartis Business Overview
Table 108. Novartis Malignant Melanoma Drugs Product
Table 109. Novartis Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 110. Novartis Recent Development
Table 111. Ono Pharmaceutical Company Details
Table 112. Ono Pharmaceutical Business Overview
Table 113. Ono Pharmaceutical Malignant Melanoma Drugs Product
Table 114. Ono Pharmaceutical Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 115. Ono Pharmaceutical Recent Development
Table 116. Amgen Company Details
Table 117. Amgen Business Overview
Table 118. Amgen Malignant Melanoma Drugs Product
Table 119. Amgen Revenue in Malignant Melanoma Drugs Business (2016-2021) & (US$ Million)
Table 120. Amgen Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Melanoma Drugs Market Share by Type: 2020 VS 2027
Figure 2. Immunotherapy Features
Figure 3. Targeted Therapy Features
Figure 4. Other Features
Figure 5. Global Malignant Melanoma Drugs Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Other Case Studies
Figure 9. Malignant Melanoma Drugs Report Years Considered
Figure 10. Global Malignant Melanoma Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Malignant Melanoma Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Malignant Melanoma Drugs Market Share by Regions: 2020 VS 2027
Figure 13. Global Malignant Melanoma Drugs Market Share by Regions (2022-2027)
Figure 14. Global Malignant Melanoma Drugs Market Share by Players in 2020
Figure 15. Global Top Malignant Melanoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Melanoma Drugs as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Malignant Melanoma Drugs Revenue in 2020
Figure 17. Global Malignant Melanoma Drugs Revenue Market Share by Type (2016-2021)
Figure 18. Global Malignant Melanoma Drugs Revenue Market Share by Type (2022-2027)
Figure 19. North America Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Malignant Melanoma Drugs Market Share by Type (2016-2027)
Figure 21. North America Malignant Melanoma Drugs Market Share by Application (2016-2027)
Figure 22. North America Malignant Melanoma Drugs Market Share by Country (2016-2027)
Figure 23. United States Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Malignant Melanoma Drugs Market Share by Type (2016-2027)
Figure 27. Europe Malignant Melanoma Drugs Market Share by Application (2016-2027)
Figure 28. Europe Malignant Melanoma Drugs Market Share by Country (2016-2027)
Figure 29. Germany Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Malignant Melanoma Drugs Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Malignant Melanoma Drugs Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Malignant Melanoma Drugs Market Share by Region (2016-2027)
Figure 39. China Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Malignant Melanoma Drugs Market Share by Type (2016-2027)
Figure 47. Latin America Malignant Melanoma Drugs Market Share by Application (2016-2027)
Figure 48. Latin America Malignant Melanoma Drugs Market Share by Country (2016-2027)
Figure 49. Mexico Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Malignant Melanoma Drugs Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Malignant Melanoma Drugs Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Malignant Melanoma Drugs Market Share by Country (2016-2027)
Figure 55. Turkey Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Malignant Melanoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Bristol-Myers Squibb Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 59. Enzon Pharmaceuticals Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 60. Exelixis Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 61. GlaxoSmithKline Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 62. Merck Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 63. Pfizer Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 64. Janssen Biotech Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 65. Hoffmann-La Roche Ltd Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 66. Navidea Biopharmaceuticals Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 67. Novartis Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 68. Ono Pharmaceutical Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 69. Amgen Revenue Growth Rate in Malignant Melanoma Drugs Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
世界の黒色腫治療薬市場規模・現状・予測（2021年-2027年） Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of…- 世界の悪性神経膠腫治療薬市場規模・現状・予測（2021年-2027年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- 世界の悪性神経膠腫治療薬市場規模・現状・予測（2021年-2027年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- 世界の黒色腫治療薬市場 2021：企業別、地域別、種類・用途別 The Melanoma Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, rec…
- 世界の悪性中皮腫治療薬市場規模・現状・予測（2021年-2027年） Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the foreca…